1. Home
  2. BHVN

as of 02-26-2026 3:38pm EST

$11.25
$0.27
-2.30%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Founded: 2013 Country:
United States
United States
Employees: N/A City: NEW HAVEN
Market Cap: 1.6B IPO Year: 2022
Target Price: $27.69 AVG Volume (30 days): 1.9M
Analyst Decision: Buy Number of Analysts: 14
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -5.74 EPS Growth: -61.95
52 Week Low/High: $7.48 - $37.36 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -2.01 Index: N/A
Free Cash Flow: -586502000.0 FCF Growth: N/A

AI-Powered BHVN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 66.26%
66.26%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: